Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "pathology-business"

2 News Found

Thyrocare Q4 PAT surges 128% to Rs. 48.7 crore
Healthcare | May 08, 2026

Thyrocare Q4 PAT surges 128% to Rs. 48.7 crore

Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands

Vijaya Diagnostic Q4FY26 revenue jumps 27%, EBITDA margin expands to 43.5%
Healthcare | May 08, 2026

Vijaya Diagnostic Q4FY26 revenue jumps 27%, EBITDA margin expands to 43.5%

With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Shilpa Biologicals' PartnerPower promises real-time transparency in biologics development

KIMS Hospitals launches RENOVA Oncology Institute in Bengaluru

Teva submits FDA application for experimental Tourette syndrome treatment ecopipam

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited

Packaging